StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Free Report) in a report released on Friday. The firm issued a hold rating on the biotechnology company’s stock.
Bellerophon Therapeutics Price Performance
NASDAQ:BLPH opened at $0.01 on Friday. Bellerophon Therapeutics has a 1-year low of $0.01 and a 1-year high of $0.02. The company has a market capitalization of $146,796.00, a PE ratio of -0.01 and a beta of 0.74. The firm’s 50-day moving average price is $0.03 and its 200-day moving average price is $0.04.
Bellerophon Therapeutics Dividend Announcement
The company also recently announced a dividend, which was paid on Wednesday, December 18th. Shareholders of record on Friday, December 20th were issued a $0.019 dividend. The ex-dividend date of this dividend was Thursday, December 19th. This represents a yield of 117.8%.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
Featured Articles
- Five stocks we like better than Bellerophon Therapeutics
- How to Invest in Small Cap Stocks
- Insiders Are Selling, But These 3 Stocks Are Must-Buys
- Where to Find Earnings Call Transcripts
- Rivian Defies Doubters: Delivery Triumph Fuels Stock Surge
- Trading Halts Explained
- Hindenburg Short Report Slams Carvana Over Alleged ‘Grift’
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
